Apply now: Demonstrate a new role of IDO1 outside oncology & access our novel brain penetrant IDO1 inhibitor
09 January 2023
For a limited period, gain access to an unprecedented, unpublished Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor from our pipeline for collaborative work. IDO1’s regulation of the kynurenine pathway affects energy release in many pathological conditions ranging from autoimmune to psychiatric disorders. How would you propose to demonstrate a novel role of IDO1 in a human or animal disease outside oncology?
Our IDO1 inhibitor BI-5668 is a small molecule compound that potently inhibits its activity in human cells and/or humanized models. What makes this IDO1 inhibitor special is that data have shown that it crosses the blood-brain-barrier. We think this makes the compound especially suitable for scientific hypotheses that cannot be addressed through first-generation IDO inhibitors.
We are looking for proposals using primary (disease) tissues, non-rodent models, or humanized models. The right answer may address any disease area where IDO1 activity may have an implication, including psychiatric, neurodegenerative, cardiovascular, or autoimmune disorders.
Selected applicants will get access to this IDO1 inhibitor free of charge, in the amount required for in vitro and in vivo experiments, together with in depth information on the molecule. Besides, you will get to directly interact with Boehringer Ingelheim scientists and benefit from direct access to their expertise. Due to the competitive nature of this call, we plan to fund the winning proposal(s) up to 250,000 euros for a fruitful collaboration.
Apply soon as your proposals can only be accepted if they arrive by March 14, 2023 11:59 pm PST.
No registration required for download
Subscribe to our newsletter to stay updated as we add new molecules to opnMe.com.
About our call for “Molecules for Collaboration”:
On opnMe, we now offer BI-5668, a highly potent and selective orally available, brain penetrant small molecule that inhibits the enzymatic activity of indoleamine 2,3-dioxygenase 1 (IDO1) and is suitable for investigations in vitro and in vivo. We invite you to propose a new disease-related hypothesis for BI-5668 through March 14 to access the molecule and additionally, get funded. Learn more…
About opnMe:
opnMe.com, the new open innovation portal of Boehringer Ingelheim, aims to accelerate research initiatives to enable new insights of disease biology in areas of high unmet medical need by sharing well-characterized molecules and offer collaborations for science. In the spirit of collaboration, our molecules are provided to the scientific community to help unlock and fulfill their full potential. These molecules are either freely available as “Molecules to Order” or applied via scientific research submissions as “Molecules for Collaboration”. As part of our third pillar, our “opn2EXPERTS” program, we also enlist scientific advice on key biologic issues to fuel further drug discovery and deliver novel solutions that benefit unmet patient needs, such as our latest question on reducing water and energy consumption in downstream bioprocesses.